Griguolo, G. http://orcid.org/0000-0002-8782-4509
Serna, G. http://orcid.org/0000-0003-2666-0982
Pascual, T. http://orcid.org/0000-0001-8431-3183
Fasani, R.
Guardia, X.
Chic, N.
Paré, L.
Pernas, S.
Muñoz, M.
Oliveira, M. http://orcid.org/0000-0001-9152-8799
Vidal, M. http://orcid.org/0000-0003-1992-5727
Llombart-Cussac, A.
Cortés, J.
Galván, P.
Bermejo, B.
Martínez, N.
López, R.
Morales, S. http://orcid.org/0000-0001-7445-4193
Garau, I.
Manso, L. http://orcid.org/0000-0002-1683-550X
Alarcón, J.
Martínez, E.
Villagrasa, P.
Prat, A. http://orcid.org/0000-0003-2377-540X
Nuciforo, P. http://orcid.org/0000-0003-1380-0990
Article History
Received: 10 September 2020
Accepted: 18 February 2021
First Online: 19 March 2021
Competing interests
: A.P. reports consulting fees from Nanostring Technologies, Roche, Pfizer, Oncolytics Biotech, Puma, Lilly, AstraZeneca, Seattle Genetics, Novartis, Amgen, BMS, MSD and Daiichi Sankyo outside the submitted work. P.N. reports consulting fees of advisory boards from Bayer, MSD and Novartis and speaker fees from MSD and Novartis. All other authors declared no competing interest.